Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SoFi Technologies Inc (SOFI) vs Zoetis Inc (ZTS) Price & Performance

SoFi Technologies IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

SoFi Technologies Inc vs Zoetis Inc — how do they compare? SoFi Technologies Inc trades at $15.75 (market cap $20.16B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and Zoetis Inc for 70 Days on average.

SOFIZTS
Market Cap
$20.16B$30.20B
Volume
49,646,3316,175,327
Sector
FinancialsHealth
52-Week High
$32.21$147.53
52-Week Low
$15.15$69.09
Typical Hold Time
60 Days70 Days
Enterprise Value
$20.30B$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SoFi Technologies Inc

SoFi Technologies trades at $15.80, up 0.89% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $2.6B in 2024 to $3.6B in 2025, though net income dipped to $481M. Analyst consensus is mixed with 37% buy ratings but a $21.58 price target suggesting 37% upside. Recent news highlights stablecoin initiatives and record loan originations amid sector volatility.

SoFi presents a growth story with expanding financial services but faces execution risks in a competitive fintech landscape. The stock's current valuation at 31.86 P/E reflects optimism about future profitability, though negative operating cash flows and rising yields create headwinds. Upside depends on sustained loan growth and successful monetization of new products like SoFiUSD.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SOFI
69% Buy31% Sell
Avg holding period · 60 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About SoFi Technologies Inc

SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.

Read more on SOFI →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →